There are 2949 resources available
1528P - Phase I trial of the first-in-class agent CEND-1 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer
Presenter: Andrew Dean
Session: E-Poster Display
Resources:
Abstract
1529P - First-line (1L) liposomal irinotecan + 5 fluorouracil/leucovorin (5-FU/LV) + oxaliplatin (OX) in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (mPDAC): Exploratory subgroup analyses of survival by changes in CA 19-9 levels
Presenter: Andrew Dean
Session: E-Poster Display
Resources:
Abstract
1530P - Gemcitabine/nab-paclitaxel versus (modified) FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis
Presenter: Jakob Riedl
Session: E-Poster Display
Resources:
Abstract
1531P - FOLFIRINOX relative dose intensity (RDI) and disease control in advanced pancreatic cancer patients (APC)
Presenter: Antonin Vary
Session: E-Poster Display
Resources:
Abstract
1532P - Nab-paclitaxel plus S1 with or without sintilimab in metastatic pancreatic ductal adenocarcinoma: A single-center, retrospective study
Presenter: Qu Liu
Session: E-Poster Display
Resources:
Abstract
1533P - Real-life data from the platform for outcome, quality of life and translational research on pancreatic cancer - PARAGON
Presenter: Salah-Eddin Al-Batran
Session: E-Poster Display
Resources:
Abstract
1534P - Multivariable analysis of real-world clinical outcomes associated with dose reductions (DRs) for patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan
Presenter: Laith Abushahin
Session: E-Poster Display
Resources:
Abstract
1535P - Paclitaxel based intraperitoneal chemotherapy for gastric and pancreatic cancer with peritoneal metastases achieves higher conversion surgery rate and longer survival
Presenter: Koya Sawai
Session: E-Poster Display
Resources:
Abstract
1536P - Chemotherapy vs best supportive care in octogenarian and older stage IV pancreatic cancer patients
Presenter: Antonino Carmelo Tralongo
Session: E-Poster Display
Resources:
Abstract
1537P - Phase I/II study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer
Presenter: Niels Halama
Session: E-Poster Display
Resources:
Abstract